
    
      This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects
      who meet all eligibility criteria will be randomly assigned to 1 of 2 treatment groups,
      rabeprazole extended release 50 mg (once daily) or ranitidine 150 mg (twice daily).

      Please note that this study is not a duplicate of E3810-G000-305; this is a separate study
      being conducted along with -305.
    
  